A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., a company based in Edmonton. Aurora has formed a special committee to evaluate the unsolicited bid from Curaleaf Holdings Inc., which aims to purchase all shares of Aurora.
Curaleaf, headquartered in Stamford, Connecticut, shared that the potential merger would result in a combined cannabis entity operating in 17 countries worldwide. Despite attempts to negotiate privately with Aurora, Curaleaf decided to publicly announce its proposal after facing resistance from Aurora’s leadership.
Curaleaf offered to pay Aurora shareholders $4 US per share along with an additional $0.75 US cash for each share. However, Aurora clarified that while it received letters from Curaleaf outlining acquisition proposals on June 23 and July 7, the financial terms were only detailed in the latter correspondence.
In response to Curaleaf’s claim of Aurora’s lack of engagement, Aurora mentioned ongoing communication between their lead independent director and Curaleaf’s CEO. Aurora emphasized its commitment to executing its business strategy in the short to medium term while not discouraging future discussions with Curaleaf.
Aurora plans to establish a special committee of independent directors to assess the bid’s viability and its impact on stakeholders. While expressing uncertainty about reaching a deal, Aurora assured that its operations would continue as usual during this process.
Although Curaleaf’s interest in the acquisition is viewed positively, analysts from TD Cowen believe that the current offer undervalues Aurora’s long-term potential. They highlighted Aurora’s market leadership in medical cannabis, robust product range, strong financial position, and adeptness in navigating global regulatory frameworks as factors that could yield substantial value over time.
Curaleaf’s CEO, Boris Jordan, sees a merger between the two companies as a means to unlock value by leveraging Curaleaf’s global distribution network with Aurora’s expertise in international medical cannabis and production capabilities. The combined revenue of both companies exceeded $1.5 billion US in the last year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the proposed acquisition.
Jordan believes that the merger offers a mutually beneficial opportunity for shareholders of both Curaleaf and Aurora, providing a diversified global platform and exposure to favorable U.S. regulatory trends.
